4151-62-6

Upstream product

• 37405-22-4 2-(1,1-dimethylethyl)-2,5-cyclohexadiene-1,4-dione 4-oxime 
• 88-18-6 2-tert-Butylphenol 

Downstream Products

• 4151-47-7 N-<3-(1,1-dimethylethyl)-4-hydroxyphenyl>acetamide 
• 4151-48-8 2-tert-Butyl-4-tosylaminophenol 
• 222853-24-9 2-tert-Butyl-4-tosylimino-1,4-benzoquinone 
• 222853-30-7 2-tert-Butyl-4-tosylimino-6-chloro-1,4-benzoquinone 
• 222853-27-2 2-tert-Butyl-4-tosylamino-6-chlorophenol 
• 107244-77-9 2-tert-Butyl-4-(7-chloro-quinolin-4-ylamino)-6-diethylaminomethyl-phenol 
• 107244-85-9 2-tert-Butyl-4-(7-chloro-1-oxy-quinolin-4-ylamino)-6-diethylaminomethyl-phenol 
• 107244-68-8 4-Amino-2-tert-butyl-6-diethylaminomethyl-phenol; hydrochloride 
• 749168-68-1 N-(3-tert-Butyl-5-diethylaminomethyl-4-hydroxy-phenyl)-acetamide 

Relevant academic research and scientific papers

Discovery and SAR study of 3-(tert-butyl)-4-hydroxyphenyl benzoate and benzamide derivatives as novel farnesoid X receptor (FXR) antagonists

3-(tert-Butyl)-4-hydroxyphenyl 2,4-dichlorobenzoate (1) was discovered in our in-house high throughput screening as a moderate FXR antagonist. To improve the potency and the stability of the hit 1, forty derivatives were synthesized and SAR was systematically explored. The results turn out that replacing the 2,4-dichlorophenyl with 2,6-dichloro-4-amidophenyl shows great improvement in potency, replacing the benzoate with benzamide shows improvement in stability and slight declining of potency and 3-(tert-butyl)-4-hydroxyphenyl unit is essential in obtaining the FXR antagonistic activity.